The Effect of Omalizumab on Allergic Rhinitis Symptoms: A Comparative Study

INTRODUCTION: Both Omalizumab and (Montelukast+Desloratadine) are effective treatments for allergic rhinitis. However, these treatments have not been compared clinically. Therefore, we aimed to compare their efficacy on allergic rhinitis symptoms.
METHODS: Between December 2018 and November 2019, 25 patients with both allergic rhinitis and chronic urticaria and 25 patients with allergic rhinitis alone were included in the study. Patients with both allergic rhinitis and chronic urticaria received Omalizumab (300 mg/month) (Omalizumab group), while patients with allergic rhinitis alone received (Montelukast+Desloratadine)/daily (Desloratadine group). In addition, both groups received fluticasone propionate nasal spray (100 mcg/day in each nostril). At baseline and after 8-10 weeks (follow-up), symptoms and quality of life were assessed. A visual analogue scale was used for the assessments.
RESULTS: Compared to baseline, both groups showed significant symptomatic improvements at follow-up. When the change from baseline to follow-up was compared, the groups were similar in terms of nasal congestion, rhinorrhoea, sneezing and quality of life (p>0.05). However, Omalizumab group was superior to Desloratadine group in terms of eye itching (68.55±17.62 vs 55.46±20.42; p=0.010).
DISCUSSION AND CONCLUSION: In conclusion, Omalizumab is more effective than Montelukast plus Desloratadine for eye itching in allergic rhinitis.

Keywords: Omalizumab, Montelukast, Desloratadine, rhinitis, comparative study.